To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma

Completed

Conditions studied: Renal Cell Carcinoma

In brief

To assess how dose reductions or treatment interruptions related to axitinib can be implemented to manage and resolve adverse events occurring among patients with advanced renal cell carcinoma treated with first-line axitinib in combination with avelumab or pembrolizumab

Key facts

Study ID

NCT04682587

Run by

Pfizer

People needed

481

Starts

2021-02-24

Expected to finish

2021-04-05

Last updated by the study team

2025-01-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Physicians meeting the following criteria will be invited to participate in the chart review study:
• Specialty in oncology
• Access to complete medical records for at least one patient with advanced RCC who meets the patient eligibility criteria
• Eligible oncologists will be asked to select up to three patients meeting the following criteria for inclusion in the chart review study:
• Confirmed diagnosis with advanced RCC
• Treated with first-line axitinib/IO combination therapy at or after diagnosis
• Experienced at least one AE (i.e., diarrhea, fatigue, nausea, hypertension, and palmar-plantar erythrodysesthesia [hand-foot syndrome]) while treated with axitinib/IO combination therapy
• Age 18 years or older at the time of advanced RCC diagnosis
• Initiated axitinib/IO combination therapy at least 3 months prior to the start date of medical chart abstraction to ensure sufficient follow-up time

You may not qualify if…

• There are no exclusion criteria for this study

Where it is running

• Pfizer — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.